Non-muscle invasive bladder cancer (NMIBC) is the most common form of bladder cancer with frequent recurrences and risk for progression. Risk stratified treatment and surveillance protocols are often utilized to guide management. In 2017, this journal reviewed guidelines on NMIBC from four major organizations: the American Urological Association (AUA)/ Society of Urologic Oncology (SUO), the European Association of Urology (EAU), the National Comprehensive Cancer Network (NCCN), and the National Institute for Health and Care Excellence (NICE). This update will review major changes in the guidelines and broadly summarize new recommendations for treatment of NMIBC in an era of BCG shortage and immense novel therapy development.

BJU international. 2019 Oct 09 [Epub ahead of print]

Jacob Taylor, Ezequiel Becher, Gary D Steinberg

Department of Urology, NYU Langone Health, NY, USA.